Comparison of novel cannabinoid partial agonists and SR141716A in the guinea‐pig small intestine
- 1 February 2000
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (4) , 645-652
- https://doi.org/10.1038/sj.bjp.0703094
Abstract
The controversial nature of the CB(1) receptor antagonist, SR141716A, in the guinea-pig small intestine was investigated by comparing it with four analogues of Delta(8)-tetrahydrocannabinol (Delta(8)-THC): O-1184, O-1238, O-584 and O-1315. These compounds (10 - 1000 nM) inhibited the electrically-evoked contractions with a rank order of potency of O-1238>O-1184>O-584>O-1315. Log concentration-response curves for O-1238, O-1184 and O-1315 were significantly shifted to the right by SR141716A and the maxima were significantly less than that of the CB(1) agonist, WIN55212-2, an indication of partial agonism. Partial saturation of the triple bond in O-1184 to a cis double bond (O-1238) increased its potency as an agonist (pEC(50) from 6.42 to 7.63) and as an antagonist of WIN55212-2, (pK(B), from 8.36 to 9.49). Substitution of the terminal azide group by an ethyl group (O-584) or removal of the phenolic hydroxyl group (O-1315) had no significant effect on the agonist or antagonist potency. None of these analogues increased the twitch response in a manner resembling that of SR141716A. O-1184 (10 and 100 nM) shifted the log concentration-response curve of WIN55212-2 for inhibition of the twitch responses to the right with pK(B) values of 8.29 and 8.38, respectively. We conclude that these Delta(8)-THC analogues behave as partial agonists rather than silent antagonists at CB(1) binding sites in this tissue. There was no evidence of antagonism of endocannabinoids thus supporting the hypothesis that, in this tissue, SR141716A is an inverse agonist of constitutively active CB(1) receptors.Keywords
This publication has 23 references indexed in Scilit:
- Cannabinoid-Precipitated Withdrawal: A Time-Course Study of the Behavioral Aspect and Its Correlation with Cannabinoid Receptors and G Protein ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2025
- Cannabinoid modulation of intestinal propulsion in miceEuropean Journal of Pharmacology, 1998
- SR141716A is an inverse agonist at the human cannabinoid CB1 receptorEuropean Journal of Pharmacology, 1997
- A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1Journal of Biological Chemistry, 1997
- Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea‐pig myenteric plexusBritish Journal of Pharmacology, 1997
- SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated miceEuropean Journal of Pharmacology, 1997
- Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladderBritish Journal of Pharmacology, 1996
- Further evidence for the presence of cannabinoid CB1 receptors in guinea‐pig small intestineBritish Journal of Pharmacology, 1996
- Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysisLife Sciences, 1996
- Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptorsBiochemical Pharmacology, 1995